Royal Bank of Canada’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Royal Bank of Canada’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,750	Closed	-$3K	–	7004
2016 Q3	$3K	Buy	+8,750	New	+$3K	﹤0.01%	6143
2016 Q1	–	Sell	-224	Closed	–	–	7079
2015 Q4	$0	Sell	224 -7,685	-97%	–	﹤0.01%	7231
2015 Q3	$12K	Sell	7,909 -1,942	-20%	-$2.95K	﹤0.01%	5832
2015 Q2	$17K	Buy	9,851 +9,184	+1,377%	+$15.8K	﹤0.01%	5801
2015 Q1	$1K	Buy	667 +618	+1,261%	+$927	﹤0.01%	6073
2014 Q4	$0	Buy	+49	New	–	﹤0.01%	6608
2014 Q1	–	Sell	-5,000	Closed	-$25K	–	6471
2013 Q4	$25K	Buy	5,000 +3,837	+330%	+$19.2K	﹤0.01%	5172
2013 Q3	$3K	Sell	1,163 -4,790	-80%	-$12.4K	﹤0.01%	5827
2013 Q2	$13K	Buy	+5,953	New	+$13K	﹤0.01%	5198

Royal Bank of Canada's RXII Position: Q4 2016 in Review

Royal Bank of Canada sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 8,750 shares — an estimated $3K sold.

Royal Bank of Canada first reported a position in RXII in Q2 2013 and held it in 9 quarters. The position peaked at $25K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

Royal Bank of Canada reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
Royal Bank of Canada sold 8,750 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $3K.
Royal Bank of Canada first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 9 quarters.
Royal Bank of Canada's GALENA BIOPHARMA INC COM position peaked at $25K in Q4 2013.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Royal Bank of Canada's 13F filing for Q4 2016, filed 14 Feb 2017.